Argenx Se (ARGX) EBITDA Margin (2016 - 2026)
Argenx Se's (ARGX) quarterly EBITDA Margin came in at 31.68% in Q2 2026, up 1049.0% YoY from 2.76% in Q2 2025, and up 4.38% on a QoQ basis from 30.35% in Q1 2026.
Powered by 
Analysis
Argenx Se (ARGX) EBITDA Margin (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of EBITDA Margin data on file, last reported at 31.68% in Q2 2026.
- Quarterly EBITDA Margin rose 1049.0% year-over-year to 31.68% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 30.4% (up 1539.0% YoY) and the FY2025 annual result came in at 24.81%, up 2577.0% from the prior year.
- EBITDA Margin improved to 31.68% in Q2 2026, from 30.35% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 47.58% in Q1 2023 to a low of 1052.43% in Q1 2022.
- A 5-year average of 78.82% and a median of 3.52% in 2024 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 2000000000 bps in 2022, down 2000000000 bps in 2022.
- Tracing ARGX's EBITDA Margin over 5 years: stood at 65.99% in 2022, then surged by 44 bps to 37.03% in 2023, then surged by 138 bps to 13.98% in 2024, then surged by 104 bps to 28.59% in 2025, then gained by 11 bps to 31.68% in 2026.
- The last three EBITDA Margin figures came in at 31.68% (Q2 2026), 30.35% (Q1 2026), and 28.59% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 19.75% |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -0.36% |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn | 41.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.54% |
| Mar 31, 2026 | 30.35% |
| Dec 31, 2025 | 28.59% |
| Sep 30, 2025 | 30.72% |
| Jun 30, 2025 | 21.20% |
| Mar 31, 2025 | 17.59% |
| Dec 31, 2024 | 13.98% |
| Sep 30, 2024 | 2.48% |
| Jun 30, 2024 | -9.52% |
| Mar 31, 2024 | -23.46% |
| Dec 31, 2023 | -37.03% |
| Sep 30, 2023 | -24.49% |
| Jun 30, 2023 | -37.91% |
| Mar 31, 2023 | -47.58% |
| Dec 31, 2022 | -65.99% |
| Sep 30, 2022 | -158.87% |
| Jun 30, 2022 | 113.83% |
| Mar 31, 2022 | -1,052.43% |
| Dec 31, 2021 | -887.37% |
| Sep 30, 2021 | 829.05% |